Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2025-01-14 Regulatory Filings
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
Regulatory Filings Classification · 90% confidence The document is a press release from Vivoryon Therapeutics providing an R&D update on their clinical pipeline, specifically regarding kidney disease studies (VIVIAD and VIVA-MIND) and patent portfolio developments. It includes data summaries, strategic priorities for 2025, and mentions an upcoming investor presentation. While it mentions an investor presentation, the document itself is a corporate announcement of research progress and strategic updates, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like Earnings Release (no quarterly financial results) or Investor Presentation (it is a text-based press release, not the presentation deck itself).
2025-01-14 English
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
Earnings Release Classification · 100% confidence The document explicitly states it reports 'financial results for the nine-month period ended September 30, 2024,' and provides detailed financial figures (Revenues, R&D expenses, Net loss) and cash position updates. This strongly indicates a periodic financial report. Since the period is nine months (not a full year), it aligns with the definition of an Interim/Quarterly Report (IR). Although it contains operational updates and mentions an upcoming conference call, the core purpose is the financial reporting for the nine-month period ending Q3 2024. It is not a full 10-K, nor is it just an announcement of a report (RPA/RNS), as it contains the actual financial data. It is more comprehensive than a simple Earnings Release (ER) which usually contains only key highlights. 9M 2024
2024-12-10 English
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
Earnings Release Classification · 100% confidence The document is a press release announcing the 'encouraging results' of a Phase 2a clinical study (SAPHIR) for a drug candidate (PQ912) targeting Alzheimer's disease. It details safety, tolerability, and exploratory endpoint results (CSF biomarkers, EEG, NTB). The text concludes with quotes from management and the Principal Investigator, and importantly, announces a public conference call to discuss these results. This structure—a detailed announcement of periodic financial/operational results (clinical trial outcomes) accompanied by a call invitation—is characteristic of an Earnings Release (ER) or a specific operational update that functions similarly to an ER, focusing on key performance indicators (trial results). Since the document provides the core results and is not just a short announcement *about* a report (ruling 2), it is classified as an Earnings Release (ER). It is not a full Annual Report (10-K) or an Interim Report (IR) as it focuses on a specific clinical event rather than comprehensive period financials. Q2 2017
2024-11-20 English
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
Earnings Release Classification · 99% confidence The document is a press release dated October 26, 2024, announcing highlights from a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 regarding Phase 2b results for the drug Varoglutamstat on kidney function. It details clinical trial data (eGFR improvement, safety profile) and outlines next steps for future studies. This content structure—announcing key scientific/clinical data presentation highlights, often including preliminary efficacy and safety findings, and future development plans—is characteristic of an Earnings Release (ER) or a general press release summarizing scientific progress. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing announcement (RNS/RPA), and it focuses on summarizing recent results and future strategy updates for investors, it aligns best with an Earnings Release (ER) which often includes operational and clinical updates alongside financial context (though financials are minimal here, the focus is on results presentation). Given the context of presenting clinical trial results, it is a form of operational/results announcement. If a specific 'Clinical Trial Results Announcement' category existed, it would fit there, but among the provided options, 'ER' (Earnings Release, often used broadly for period results announcements) or 'IP' (Investor Presentation, as it summarizes presentation content) are possibilities. However, since it is a press release announcing results presented at a conference, it functions as a key update for investors, making ER the most appropriate fit for a major operational/results announcement, even if not strictly tied to a quarterly earnings period. It is not a formal Investor Presentation (IP) document itself, but a summary of one. It is not a Management Discussion & Analysis (MDA) as it lacks deep management commentary on overall business trends beyond the trial. Therefore, ER is the best fit for a major results announcement press release. H1 2024
2024-10-28 English
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Vivoryon Therapeutics N.V.'s abstract regarding their drug Varoglutamstat has been selected for an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024. This is an announcement about participation in a scientific/medical conference, detailing the presentation title, author, session, and time. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a proxy statement or dividend notice. Since it is an announcement related to company activities and scientific progress, and it doesn't fit the specific categories like ER, IR, or CT, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a type of Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* a presentation. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-financial, non-management-change news that is publicly disseminated via press release.
2024-10-11 English
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
Regulatory Filings Classification · 100% confidence The document is a press release dated October 1, 2024, summarizing key takeaways from a virtual Key Opinion Leader (KOL) event focused on kidney disease and the company's drug candidate, varoglutamstat. It details scientific insights, market dynamics, and clinical data observations. This type of communication, which provides updates on R&D progress, scientific events, and pipeline developments to investors, aligns best with an Investor Presentation (IP) or a general Earnings Release (ER) if it contained financial results. Since it is a summary of a scientific/clinical event rather than a formal financial report (10-K, IR) or a brief financial highlight announcement (ER), and it is structured like a detailed update for investors, 'Investor Presentation' (IP) is the most fitting category, although it is presented as a press release. Given the content focuses heavily on scientific data, KOL perspectives, and future clinical plans, it functions as an investor update presentation summary. It is not a formal regulatory filing like 10-K or a simple earnings announcement (ER). It is a detailed update, making IP more appropriate than ER.
2024-10-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.